Bell Potter Sticks to Their Buy Rating for Mesoblast Limited (MEOBF)
Mesoblast Analyst Ratings
Piper Sandler Maintains Mesoblast(MESO.US) With Buy Rating, Announces Target Price $11
Mesoblast (MESO) Receives a Buy From Piper Sandler
Mesoblast Price Target Raised to $11.00/Share From $4.00 by Piper Sandler
Mesoblast Analyst Ratings
Piper Sandler Upgrades Mesoblast(MESO.US) to Buy Rating
Mesoblast Limited (MEOBF) Was Downgraded to a Hold Rating at Jefferies
Mesoblast Analyst Ratings
Mesoblast Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Aprea Therapeutics (APRE), Biogen (BIIB) and Mesoblast Limited (OtherMEOBF)
Mesoblast (MESO) Gets a Hold From Piper Sandler
Mesoblast Limited (MEOBF) Receives a Buy From Jefferies
Mesoblast (MESO) Gets a Hold From Piper Sandler
Jefferies Keeps Their Buy Rating on Mesoblast Limited (MEOBF)
Analysts Are Bullish on These Healthcare Stocks: Guangzhou Baiyunshan Pharmaceutical Holdings Company (GZPHF), Mesoblast Limited (MEOBF)
Analysts Offer Insights on Healthcare Companies: Haemonetics (HAE), Mesoblast (MESO) and HealthStream (HSTM)
Cantor Fitzgerald Reiterates Overweight on Mesoblast, Maintains $17 Price Target
Mesoblast Analyst Ratings
Analyst Bullish On Cell Therapy Player Mesoblast, But Cuts Price Target
No Data